10.1002/chem.202003471
Chemistry - A European Journal
FULL PAPER
[28] C. D. Smith, X. Zhang, S. L. Mooberry, G. M. L. Patterson, R. E. Moore,
Cancer Res. 1994, 54, 3779 – 3784.
Acknowledgements
[29] D. Panda, V. Ananthnarayan, G. Larson, C. Shih, M. A. Jordan, L. Wilson,
Biochemistry 2000, 39, 14121–14127.
This project has received funding from the European Union’s Hori-
zon 2020 research and innovation programme under the Marie
Sklodowska-Curie grant agreement No 642004 (ETN
MAGICBULLET). We gratefully acknowledge MIUR (Project
PRIN20157WW5EH) and the University of Bologna for financial
support. The authors want to acknowledge Marco Wißbrock and
Anke Nieß for technical support, Dr. Georg Falck for flow cytom-
etry analysis and Dr. Jens Sproß (Department of Chemistry, Bie-
lefeld University) for mass spectrometry measurements. The M21
human melanoma cells were kindly provided by David Cheresh
and The Scripps Research Institute (La Jolla, CA, USA).
[30] M. J. Edelman, D. R. Gandara, P. Hausner, V. Israel, D. Thornton, J.
DeSanto, L. A. Doyle, Lung cancer 2003, 39, 197–199.
[31] G. D’Agostino, J. Del Campo, B. Mellado, M. A. Izquierdo, T. Minarik, L.
Cirri, L. Marini, J. L. Perez-Gracia, G. Scambia, Int. J. Gynecol. Cancer
2006, 16, 71–76.
[32] V. A. Verma, T. H. Pillow, L. DePalatis, G. Li, G. L. Phillips, A. G. Polson,
H. E. Raab, S. Spencer, B. Zheng, Bioorg. Med. Chem. Lett. 2015, 25,
864–868.
[33] A. Bigot, H. Bouchard, M.-P. Brun, F. Clerc, J. Zhang, Novel Cryptophy-
cin Compounds and Conjugates, Their Preparation and Their Therapeu-
tic Use. WO 2017/076998 A1, 2017.
[34] D. Su, K. R. Kozak, J. Sadowsky, S.-F. Yu, A. Fourie-O’Donohue, C.
Nelson, R. Vandlen, R. Ohri, L. Liu, C. Ng, et al., Bioconjug. Chem. 2018,
29, 1155–1167.
Keywords: antitumor agents • β-glucuronidase • drug delivery •
integrin • small molecule drug conjugates
[35] M. C. Steinkühler, M. P. Gallinari, B. Osswald, N. Sewald, M. Ritzefeld,
M. Frese, E. Figueras, L. Pethő, Cryptophycin-Based Antibody-Drug
Conjugates with Novel Self-Immolative Linkers. WO2016/146638 A1,
2016.
[1]
R. V. J. Chari, M. L. Miller, W. C. Widdison, Angew. Chem. Int. Ed. 2014,
53, 3796–3827; Angew. Chem. 2014, 126, 3872–3904.
[2]
[3]
M. Srinivasarao, P. S. Low, Chem. Rev. 2017, 117, 12133–12164.
M. Srinivasarao, C. V. Galliford, P. S. Low, Nat. Rev. Drug Discov. 2015,
14, 203–219.
[36] S. Cazzamalli, E. Figueras, L. Pethő, A. Borbély, C. Steinkühler, D. Neri,
N. Sewald, ACS Omega 2018, 3, 14726–14731.
[37] A. Borbély, E. Figueras, A. Martins, S. Esposito, G. Auciello, E. Mon-
teagudo, A. Di Marco, V. Summa, P. Cordella, R. Perego, et al., Phar-
maceutics 2019, 11, 151.
[4]
[5]
D. Böhme, A. G. Beck-Sickinger, J. Pept. Sci. 2015, 21, 186–200.
and-new-therapeutic-biological-products/new-drug-therapy-approvals-
provals-and-databases/fda-granted-accelerated-approval-belantamab-
mafodotin-blmf-multiple-myeloma (Accessed on: 28.08.2020).
J. M. Lambert, A. Berkenblit, Annu. Rev. Med. 2018, 69, 191–207.
N. Krall, J. Scheuermann, D. Neri, Angew. Chem. Int. Ed. 2013, 52,
1384–1402; Angew. Chem. 2013, 125, 1424–1443.
[38] E. Figueras, A. Martins, A. Borbély, V. Le Joncour, P. Cordella, R. Per-
ego, D. Modena, P. Pagani, S. Esposito, G. Auciello, et al., Pharmaceu-
tics 2019, 11, 220.
[39] A. Borbély, E. Figueras, A. Martins, L. Bodero, A. Raposo Moreira Dias,
P. López Rivas, A. Pina, D. Arosio, P. Gallinari, M. Frese, et al., Chem-
istryOpen 2019, 8, 737–742.
[6]
[7]
[40] A. Borbély, F. Thoreau, E. Figueras, M. Kadri, J. L. Coll, D. Boturyn, N.
Sewald, Chem. Eur. J. 2020, 26, 2602–2605.
[8]
[9]
A. Kuriakose, N. Chirmule, P. Nair, J. Immunol. Res. 2016, 2016, 1–18.
F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, R. K. Jain, V.
P. Torchilin, Cancer Res. 1995, 55, 3752–3756.
[41] J. Liang, R. E. Moore, E. D. Moher, J. E. Munroe, R. S. Al-awar, D. A.
Hay, D. L. Varie, T. Y. Zhang, J. A. Aikins, M. J. Martinelli, et al., Invest.
New Drugs 2005, 23, 213–224.
[10] C. Zhuang, X. Guan, H. Ma, H. Cong, W. Zhang, Z. Miao, Eur. J. Med.
Chem. 2019, 163, 883–895.
[42] R. P. Lyon, T. D. Bovee, S. O. Doronina, P. J. Burke, J. H. Hunter, H. D.
Neff-Laford, M. Jonas, M. E. Anderson, J. R. Setter, P. D. Senter, Nat.
Biotechnol. 2015, 33, 733–735.
[11] P. T. Wong, S. K. Choi, Chem. Rev. 2015, 115, 3388–3432.
[12] M. Srinivasarao, P. S. Low, Chem. Rev. 2017, 117, 12133–12164.
[13] N. Joubert, C. Denevault-Sabourin, F. Bryden, M. C. Viaud-Massuard,
Eur. J. Med. Chem. 2017, 142, 393–415.
[43] G. E. Mudd, A. Brown, L. Chen, K. Van Rietschoten, S. Watcham, D. P.
Teufel, S. Pavan, R. Lani, P. Huxley, G. S. Bennett, J. Med. Chem. 2020,
doi: 10.1021/acs.jmedchem.9b02129.
[14] S. Cazzamalli, A. Dal Corso, D. Neri, Mol. Cancer Ther. 2016, 15, 2926–
2935.
[44] S. C. Jeffrey, J. B. Andreyka, S. X. Bernhardt, K. M. Kissler, T. Kline, J.
S. Lenox, R. F. Moser, M. T. Nguyen, N. M. Okeley, I. J. Stone, et al.,
Bioconjug. Chem. 2006, 17, 831–840.
[15] J. S. Desgrosellier, D. A. Cheresh, Nat. Rev. Cancer 2010, 10, 9–22.
[16] M. Nieberler, U. Reuning, F. Reichart, J. Notni, H.-J. Wester, M. Schwai-
ger, M. Weinmüller, A. Räder, K. Steiger, H. Kessler, Cancers 2017, 9,
116.
[45] P. J. Burke, J. Z. Hamilton, S. C. Jeffrey, J. H. Hunter, S. O. Doronina, N.
M. Okeley, J. B. Miyamoto, M. E. Anderson, I. J. Stone, M. L. Ulrich, et
al., Mol. Cancer Ther. 2017, 16, 116–123.
[17] H. Hamidi, J. Ivaska, Nat. Rev. Cancer 2018, 18, 533–548.
[18] E. Ruoslahti, M. D. Pierschbacher, Science 1987, 238, 491–497.
[19] M. D. Pierschbacher, E. Ruoslahti, Nature 1984, 309, 30–33.
[20] S. Katsamakas, T. Chatzisideri, S. Thysiadis, V. Sarli, Future Med. Chem.
2017, 9, 579–604.
[46] X. Chen, B. Wu, P. G. Wang, Curr. Med. Chem. - Anticancer Agents 2003,
3, 139–150.
[47] M. de Graaf, E. Boven, H. W. Scheeren, H. J. Haisma, H. M. Pinedo,
Curr. Pharm. Des. 2002, 8, 1391–1403.
[21] H. Chen, G. Niu, H. Wu, X. Chen, Theranostics 2016, 6, 78–92.
[22] A. Greco, L. Maggini, L. De Cola, R. De Marco, L. Gentilucci, Bioconjug.
Chem. 2015, 26, 1873–1878.
[48] I. Tranoy-Opalinski, T. Legigan, R. Barat, J. Clarhaut, M. Thomas, B. Re-
noux, S. Papot, Eur. J. Med. Chem. 2014, 74, 302–313.
[49] M. Nahrwold, C. Weiß, T. Bogner, F. Mertink, J. Conradi, B. Sammet, R.
Palmisano, S. Royo Gracia, T. Preuße, N. Sewald, J. Med. Chem. 2013,
56, 1853–1864.
[23] T. Chatzisideri, G. Leonidis, V. Sarli, Future Med. Chem. 2018, 10, 2201–
2226.
[24] L. Auzzas, F. Zanardi, L. Battistini, P. Burreddu, P. Carta, G. Rassu, C.
Curti, G. Casiraghi, Curr. Med. Chem. 2010, 17, 1255–1299.
[25] T. G. Kapp, F. Rechenmacher, S. Neubauer, O. V. Maltsev, E. A. Caval-
canti-Adam, R. Zarka, U. Reuning, J. Notni, H. J. Wester, C. Mas-Moruno,
et al., Sci. Rep. 2017, 7, 39805.
[50] P. López Rivas, C. Müller, C. Breunig, T. Hechler, A. Pahl, D. Arosio, L.
Belvisi, L. Pignataro, A. Dal Corso, C. Gennari, Org. Biomol. Chem. 2019,
17, 4705–4710.
[51] M. Grinda, J. Clarhaut, I. Tranoy-Opalinski, B. Renoux, A. Monvoisin, L.
Cronier, S. Papot, ChemMedChem 2011, 6, 2137–2141.
[52] S. Papot, I. Tranoy, F. Tillequin, J. C. Florent, J. P. Gesson, Curr. Med.
Chem. - Anticancer Agents 2002, 2, 155–185.
[26] C. Weiss, E. Figueras, A. N. Borbely, N. Sewald, J. Pept. Sci. 2017, 23,
514–531.
[27] R. E. Schwartz, C. F. Hirsch, D. F. Sesin, J. E. Flor, M. Chartrain, R. E.
Fromtling, G. H. Harris, M. J. Salvatore, J. M. Liesch, K. Yudin, J. Ind.
Microbiol. 1990, 5, 113–123.
[53] D. C. Schröder, O. Kracker, T. Fröhr, J. Góra, M. Jewginski, A. Nieß, I.
Antes, R. Latajka, A. Marion, N. Sewald, Front. Chem. 2019, 7, 155.
[54] D. A. Cheresh, R. C. Spiro, J. Biol. Chem. 1987, 262, 17703–17711.
7
This article is protected by copyright. All rights reserved.